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Abstract: Despite the substantial interest in C-glycosyl heterocycles as mimetics of biologically 
active native glycans, the appearance of C-glycopyranosyl derivatives of six-membered 
heterocycles, both in synthetic and biological contexts, is rather scarce. As part of our ongoing 
research program aimed at preparing hitherto barely known 2-C-glycopyranosyl pyrimidines, the 
goal of the present study was to synthesize new 5-mono- and multiply substituted derivatives of 
this compound class. Thus, 2-C-(β-D-glucopyranosyl)-5,6-disubstituted-pyrimidin-4(3H)-ones and 
4-amino-2-C-(β-D-glucopyranosyl)-5,6-disubstituted-pyrimidines were prepared by base-mediated 
cyclocondensations of O-perbenzylated and O-unprotected C-(β-D-glucopyranosyl) formamidine 
hydrochlorides with methylenemalonic acid derivatives. The 2-C-(β-D-glucopyranosyl)-5-
substituted-pyrimidines were obtained from the same amidine precursors upon treatment with 
vinamidinium salts. The deprotected derivatives of these pyrimidines were tested as inhibitors of 
some glycoenzymes. None of them showed inhibitory activity towards glycogen phosphorylase and 
α- and β-glucosidase enzymes, but some members of the sets exhibited moderate inhibition against 
bovine liver β-galactosidase.  
Keywords: C-Glucopyranosyl derivative; pyrimidine; amidine; glycoenzyme; inhibitor 
 
1. Introduction 
C-Glycopyranosyl heterocycles [1] are among the widely investigated groups of sugar-based 
small molecules. The intense interest in such compounds is primarily due to their possible use as 
glycomimetics [1–3]. The hydrolitically stable C-C linkage between the glycon and the heterocyclic 
aglycon part, and the ability of the heteroaromatic moiety to strengthen the binding by diverse 
interactions (e.g., hydrogen bonds, van der Waals interactions, π-π stackings, and coordination to 
metal ions) to target biomolecules, along with some general advantages derived from the presence of 
the sugar component (e.g., enhancement of the solubility, the possibility of targeting carbohydrate 
binding proteins), make these compounds very attractive in drug design [4]. 
Within this compound class, the most commonly represented ones are C-glycopyranosyl 
derivatives of five-membered heterocycles, possessing a large variety of biological effects [1]. On the 
other hand, six-membered C-glycopyranosyl heterocycles have received much less attention [1]. This 
appears to be surprising given that their C-glycofuranosyl variants, as analogues of nucleosides, 
belong to an intensively studied class of sugar conjugates [5]. This general tendency also applies to 
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C-glycosyl pyrimidines: while a great number of C-glycofuranosyl pyrimidines are known [6–11], C-
glycopyranosyl analogues are scarcely found in the literature. 
For the formation of 2-C-glycopyranosyl pyrimidines, only one example was described [12], 
wherein a Minisci type radical glycosylation of a protonated pyrimidine resulted in a 2-(3′,4′-di-O-
benzoyl-2′-deoxy-β-D-ribopyranosyl)-pyrimidine together with the corresponding 4-C-
glycopyranosylated isomer in 3:7 ratio. Some 5-C-glycopyranosyl pyrimidines were produced by 
ring-closures of C-glycopyranosylated enaminoketones with guanidine or acetamidine [13,14]. In 
addition, series of 4-C-, 6-C-, and 4,6-bis-C-glycosyl dihydropyrimidines were obtained from C-
glycopyranosyl formaldehydes or β-ketoesters by three-component Biginelli-type cyclisations 
[15,16]. 
Recently, as part of a systematic study on the syntheses of 2-C-glycopyranosyl pyrimidines (e. 
g. I and II in Figure 1), we published their first general synthesis from the corresponding O-
perbenzylated (1) or O-unprotected C-glucopyranosyl formamidines (2) as well as in a one-pot three-
step transformation of O-peracylated glycopyranosyl cyanides [17]. Some members of I and II 
exhibited moderate inhibition of some glycosidase enzymes [17], however, each proved inactive 
against glycogen phosphorylase [17]. Although these biological effects are not outstanding, these are 
the first investigations to reveal potential utilities of this novel compound class. 
As a continuation of these studies, in this paper, we disclose the preparation of 4,5,6-tri- and 5-
monosubstituted 2-C-glucopyranosyl pyrimidines (III, IV and V, respectively) by the reaction of 
amidines 1 and 2 with methylenemalonic acid derivatives and vinamidinium salts, respectively, and 
the evaluation of the resulting heterocycles as inhibitors of glycoenzymes. 
  
Figure 1. Recent syntheses of 2-C-glucopyranosyl pyrimidines yielding biologically active derivatives 
and the target compounds of this study. 
2. Results and Discussion 
2.1. Syntheses 
For the synthesis of the target trisubstituted 2-C-glucopyranosyl pyrimidines, the ring-closures 
of amidine hydrochloride 1 [18,19] with methylenemalonic acid derivatives 3–7 were investigated  
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Table 1. Ring-closure of C-(β-D-glucopyranosyl)formamidines with methylenemalonic acid 
derivatives. 
 
Reagent  Product 
      Yield (%) 
 
 
 R1 R2 R3 
10 11 
  from 10 from 2 
3  a H CN NH2 76 n.r.a 73 
4 
   
 b H COOEt NH2 37 51 20 
 c H CN OHb 30 n.r.a 45 
5 
   
 d H COOEt OHb 80 67 51 
6 
   
 e Ph CN NH2 78 n.r.a 85 
7 
 
  
 f Ph CN OHb 70 n.r.a 41 
8 
 
  
 g Ph COOMe OHb 
Due to the different outcome of the 
ring-closure of 1 with dialkyl 
benzylidenemalonates 8 and 9, the 
synthesis of compounds 10g,h and 
11g,h are presented separately in 
Scheme 1. 
9 
 
  
 h Ph COOEt OHb 
a n.r.: No reaction; b In order to depict compounds 10 and 11 in generalizable chemical formulae, the 
6-oxo-1,6-dihydropyrimidine derivatives 10c,d,f,g,h, and 11 c,d,f,g,h are shown in their tautomeric 6-
hydroxy-pyrimidine forms (R3 = OH). 
first (Table 1). Treatment of 1 with compounds 3–7 in the presence of NaOMe in MeOH at 0 °C gave 
the desired pyrimidines 10a–f, respectively, in good yields. In the reaction of 1 with ethyl 2-cyano-3-
ethoxyacrylate 4, the nucleophilic amidine attacked both the cyano and the ester groups of the 
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reagent. Thus, this cyclocondensation led to the formation of a mixture of ethyl 4-amino-pyrimidine-
5-carboxylate 10b and 6-oxo-1,6-dihydropyrimidine-5-carbonitrile 10c. Surprisingly, the same 
reaction of 1 with ethyl 2-cyano-2-phenylacrylate 7 afforded only one product 11f, derived from a 
ring-closure involving the ester group of the reagent.  
For the O-debenzylation of the new 2-glucosyl pyrimidines 10a–f, catalytic hydrogenolysis in an 
acidified EtOAc-EtOH solvent mixture at ambient temperature was attempted. Under the applied 
reductive conditions, the deprotection of compounds 10b and 10d was smoothly affected to get the 
test compounds 11b and 11d, respectively, in acceptable yields. Unfortunately, pyrimidines 10a,c,e,f 
with a 5-CN substituent remained intact under the same conditions. This might be due to a poisoning 
of the catalyst, caused by the coordination of the cyano group to the palladium. 
In order to avoid the critical deprotection in the last step of the synthesis, the preparation of the 
unprotected pyrimidines 11 was also examined in a reversed sequence, wherein the formamidine salt 
2, obtained from 1 by hydrogenolytic O-debenzylation [17], was cyclized with the corresponding 
methylenemalonic acid derivatives 3–7 (Table 1). The ring-closure of 2 with compounds 3–7 
proceeded similarly to that of amidine salt 1, providing each target test compound 11a–f in moderate 
to good yields. 
The cyclocondensations of amidine salts 1 and 2 with dialkyl benzylidenemalonates 8 and 9, 
under the same ring-closing conditions used for compounds 3–7, did not directly provide the 
expected pyrimidinone derivatives 10g,h and 11g,h (Table 1). Similarly to a literature example [20], 
compounds 8 and 9, when cyclized with 2, furnished 6-oxo-1,4,5,6-tetrahydropyrimidines 12 (Scheme 
1). Our attempts to achieve the spontaneous oxidation of compounds 12g,h to get 10g,h by using 
prolonged reaction times or higher temperatures, were unsuccessful. Finally, the transformation of 
12g,h into 10g,h was carried out by applying DDQ as an oxidant in an additional step. The removal 
of the O-benzyl protecting groups of 12g,h was then performed by hydrogenolysis over Pd(OH)2 to 
get the final products 11g,h in good yields. 
 
Scheme 1. Synthesis of alkyl 2-(β-D-glucopyranosyl)-4-phenyl-6-oxo-1,6-dihydropyrimidine-5-
carboxylates. 
The formation of 2-C-glucopyranosyl-5-substituted-pyrimidines was also envisaged starting 
from the same carbohydrate precursors 1 and 2. To this end, NaOMe-mediated cyclisations of 
compounds 1 and 2 with vinamidinium salts 13–16 were accomplished to get the desired 2,5-
disubstituted heterocycles 17 and 18, respectively, in good to high yields (Table 2). Compound 18a 
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was prepared both by the ring-closure of 1 with 13, followed by a BCl3-mediated O-debenzylation of 
the resulting pyrimidine 17a, and by a reversed debenzylation-cyclisation sequence 1→2→18a. In 
terms of the overall yields of 18a, the latter route proved to be more efficient (51% for 1→17a→18a 
vs. 80% for 1→2→18a). By applying this second synthetic pathway, high-yielding preparation of the 
test compounds 18b and 18c was also smoothly achieved (Table 2). 
Table 2. Ring-closure of C-(β-D-glucopyranosyl)formamidines with vinamidinium salts. 
 
Reagent  Product  
   Yield (%) 
   17 18 
 R n A   R’  from 17 from 2 
13 H 1 ClO4  a H 60 85 81 
14 Cl 1 PF6  b Cl 97 ni 88 
15 Br 1 ClO4  c Br 90 ni 85 
16 CH=NMe2+ 2 ClO4  d CHO 86 ni ni 
*ni: not investigated. 
In addition, further transformations of compounds 17c and 17d were carried out to get 
additional 2-C-glucopyranosyl-5-substituted-pyrimidines (Scheme 2). A Pd(PPh3)2Cl2-catalyzed 
cross-coupling of 5-bromopyrimidine 17c with phenylboronic acid furnished 5-phenylpyrimidine 
17e in excellent yield, while the oxidation of 5-formylpyrimidine 17d with NIS in the presence of 
K2CO3 and MeOH resulted in methyl pyrimidine-5-carboxylate 17f in good yield. Finally, the 
cleavage of the O-benzyl protecting groups of 17e,f was performed with BCl3 to obtain the test 
compounds 18e,f in high yields. 
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Scheme 2. Synthesis of further 2-(β-D-glucopyranosyl)-5-substituted-pyrimidines. 
2.2. Enzyme Inhibition Studies 
The new unprotected compounds 11 and 18 were tested as inhibitors of some glycoenzymes. 
Similarly to the previously tested 2-C-glucopyranosyl pyrimidines (I and II in Figure 1) [17], none of 
them exhibited inhibition against rabbit muscle glycogen phosphorylase b (rmGPb) and almond β-
glucosidase.  
While 2-(β-D-glucopyranosyl)-6-phenylpyrimidin-4(3H)-one 19 was earlier shown to be a 
submillimolar inhibitor of yeast α-glucosidase (IC50 = 0.7 mM) [17], the new analogs 11 had negligible 
effects against this enzyme. 
Depending on the substitution pattern of the pyrimidine ring, varied inhibitory potencies of 
compounds 11 and 19 were observed towards bovine liver β-galactosidase (Table 3). The enzyme 
kinetic data of the comparable pairs 11a and 11e, 11c and 11f, and 11d and 11h clearly indicated the 
beneficial effect of the presence of a phenyl substituent at the C-6 position of the pyrimidine ring: 
while compounds 11a, 11c, and 11d did not inhibit the β-galactosidase, their phenyl-substituted 
counterparts 11e, 11f, and 11h, respectively, displayed a weak but noticeable inhibition in similar 
mM concentration ranges. The inhibitory activity of 11f-h in comparison to that of 19 showed that 
the introduction of a cyano group into the C-5 position of the heterocycle did not cause any significant 
effect on the potency (19 vs. 11f), but switching to the ester groups resulted in some strengthening of 
the inhibition (19 vs. 11g and 11h). A similar slight improvement was also observed in the pair 11a 
and 11b. Compound 11h, bearing both the phenyl and the ester substituent, proved to be the best 
inhibitor of the series, displaying submillimolar inhibitory effect against this β-galactosidase enzyme. 
Among the 2-(β-D-glucopyranosyl)-5-substituted-pyrimidines, the unsubstituted 18a and the 5-
halogen-substituted heterocycles 18b,c proved to be inactive, while pyrimidines, having the phenyl 
(18e) and the methyl ester (18f) group, showed weak inhibition against the β-galactosidase enzyme 
(Table 3). Although compounds 18e and 18f had no significant effects against this enzyme, their 
moderate activities indicated that the introduction of these substituents, not only at position 6 but 
also at 5 of the pyrimidine ring could also be advantageous.  
Table 3. Inhibition of bovine liver β-galactosidase by the new 2-C-(β-D-glucopyranosyl)-pyrimidines. 
Compound Inh. Compound Inh. 
11a 
   
NI at 4.1 
mM 11e 
   
56% at 3.0 
mM 
11b 
 
  
40% at 3.6 
mM 11f 
   
40% at 3.6 
mM 
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11c 
   
NI at 3.5 
mM 11g 
 
 
85% at 3 
mM 
11d 
 
  
NI at 3.4 
mM 
11h 
 
  
86% at 2.8 
mM 
IC50 = 0.294 
± 0.05 mM 
18a 
   
NI at 2.7 
mM 18e 
   
30% at 3.6 
mM 
18b 
   
NI at 3.7 
mM 18f 
 
 
50% at 3.8 
mM 
18c 
   
NI at 3.6 
mM 
19 56% at 3.2 
mM [17] 
3. Experimental  
3.1. Syntheses 
3.1.1. General Methods 
Optical rotations were measured on a Jasco P-2000 polarimeter (Jasco, Easton, MD, USA) at rt, 
and the data were calculated as an average of three parallel measurements. NMR spectra were 
recorded with Bruker DRX360 (360/90 MHz for 1H/13C) and Bruker DRX400 (400/100 MHz for 1H/13C) 
spectrometers. Chemical shifts are referenced to Me4Si (1H) or to the residual solvent signals (13C). MS 
spectra were obtained by a Bruker Micro TOF-Q (ESI-MS) or a Bruker maXis II (ESI-HRMS) 
spectrometer. For TLC analysis, DC Alurolle Kieselgel 60 F254 plates (Merck) were used and the spots 
were visualized under UV light and by gentle heating. For column chromatographic purification, 
Kieselgel 60 silica gel (Molar Chemicals, particle size 63–200 µm) was used. Anhydrous MeOH was 
dried by distillation over Mg turnings and iodine. Anhydrous EtOH was purchased from Molar 
Chemicals and used as received. 2-(Ethoxymethylene)malononitrile (3), ethyl 2-cyano-3-
ethoxyacrylate (4), and diethyl 2-(ethoxymethylene)malonate (5) were commercially available 
chemicals (Merck). C-(2,3,4,6-Tetra-O-benzyl-β-D-glucopyranosyl)formamidine hydrochloride (1) 
[18,19], C-(β-D-glucopyranosyl)formamidine hydrochloride (2) [17], 2-benzylidenemalononitrile (6) 
[21], 2-cyano-3-phenylacrylate (7) [22], dimethyl and diethyl benzylidenemalonate (8 and 9 [22,23], 
respectively), 1,3-bis(dimethylamino)trimethinium perchlorate (13) [24], 2-chloro-1,3-
bis(dimethylamino)trimethinium hexafluorophosphate (14) [25], and 2-dimethylaminomethylene-
1,3-bis(dimethylimonio)propane diperchlorate (16) [26] were prepared according to published 
procedures. 
3.1.2. General Procedure 1 for the Synthesis of 2-(β-D-Glucopyranosyl)-pyrimidines (10 or 11) by 
Cyclisation of C-β-D-Glucopyranosyl Formamidines (1 or 2) with Substituted Methylenemalonic 
Acid Derivatives  
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To a solution of the corresponding C-(β-D-glucopyranosyl)formamidine hydrochloride (1 or 2) 
in dry MeOH (2 mL/100 mg amidine), ~1M solution of NaOMe in dry MeOH (3 equiv.) was added at 
0 °C. After stirring the reaction mixture at this temperature for 10 min, the appropriate 
methylenemalonic acid derivative (2 equiv.) was added. The completion of the reaction was 
monitored by TLC (CHCl3-MeOH = 9:1 and EtOAc-hexane = 1:1 in the case of O-perbenzylated 
derivatives and CHCl3-MeOH = 7:3 in the case of unprotected derivatives). After the disappearance 
of the starting amidine (1 or 2), the reaction mixture was neutralized with glacial acid, the solvent 
was evaporated under reduced pressure, and the residue was purified by column chromatography.  
3.1.3. General Procedure 2 for the Synthesis of Alkyl 2-(2′,3′,4′,6′-tetra-O-benzyl-β-D-glucopyra-
nosyl)-4-phenyl-6-oxo-1,4,5,6-tetrahydropyrimidine-5-carboxylates (12) by Cyclisation of C-β-D-
Glucopyranosyl Formamidine (1) with Benzylidenemalonate Derivatives  
To a solution of amidine hydrochloride 1 (400 mg, 0.66 mmol) in dry MeOH or EtOH (2.5 mL/100 
mg substrate), ~1M solution of sodium alkoxide in MeOH or EtOH (2 equiv.) was added and the 
mixture was stirred at rt for 10 min. To this mixture, the corresponding 2-benzylidenemalonate 
derivative (2 equiv.) was added and stirred at rt until the TLC (EtOAc-hexane = 1:2 and CHCl3-MeOH 
= 9:1) showed the complete conversion of 1 (~ 6 h). The reaction mixture was then neutralized with 
glacial acid, concentrated under diminished pressure, and the residue was purified by column 
chromatography. 
3.1.4. General Procedure 3 for the Oxidation of 1,4,5,6-Tetrahydropyrimidine Derivatives (12) by 
DDQ 
A 1,4,5,6-tetrahydropyrimidine derivative (12) was dissolved in dry MeOH (2 mL/100 mg 
substrate), and DDQ (1 equiv.) was added. The reaction mixture was stirred at rt and monitored by 
TLC (EtOAc-hexane = 1:2). After the total consumption of the starting material (6 h), the solvent was 
removed in vacuo. The resulting oil was dissolved in EtOAc (30 mL) and extracted with 10% aq. 
solution of NaOH (5 × 10 mL). The organic phase was dried over MgSO4, filtered, and the solvent 
was evaporated under reduced pressure. The residue was purified by column chromatography. 
3.1.5. General Procedure 4 for the Synthesis of 2-(β-D-Glucopyranosyl)-pyrimidines (17 or 18) by 
Cyclisation of C-β-D-Glucopyranosyl Formamidine Hydrochlorides (1 or 2) and Vinamidinium 
Salts  
To a solution of C-(β-D-glucopyranosyl)formamidine hydrochloride (1 or 2) in dry MeOH (2 
mL/100 mg amidine), ~1M solution of NaOMe in dry MeOH (2.1 equiv.) was added. The reaction 
mixture was stirred at rt for 10 min, then the corresponding vinamidinium salt (1.1 equiv.) was added 
and the stirring was continued at rt. After completion of the reaction judged by TLC (CHCl3-MeOH 
= 9:1 and EtOAc-hexane = 1:2 for benzylated compounds and CHCl3-MeOH = 7:3 for unprotected 
derivatives), the mixture was neutralized with glacial acetic acid, then the solvent was removed 
under diminished pressure. The residue was purified by column chromatography. 
3.1.6. Synthesis and Characterization of the New Compounds 
4-Amino-2-(2′,3′,4′,6′-tetra-O-benzyl-β-D-glucopyranosyl)-pyrimidine-5-carbonitrile (10a). Prepared 
from compound 1 (400 mg, 0.66 mmol) and 2-(ethoxymethylene)malononitrile 3 (162 mg, 1.33 mmol) 
according to genereal procedure 1. Reaction time: 30 min. The title compound precipitated from the 
reaction mixture as a pale yellow amorphous solid. Yield: 325 mg (76%). Rf = 0.55 (EtOAc-hexane = 
1:1); [α]D = ‒1 (c 0.20, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ (ppm): 8.87 (2H, br s, NH2), 8.33 (1H, s, 
H-6), 7.40–6.99 (20H, m, aromatics), 4.93, 4.89 (2 × 1H, 2d, J = 11.0 Hz in each, PhCH2), 4.92, 4.69 (2 × 
1H, 2d, J = 10.8 Hz in each, PhCH2), 4.82, 4.74 (2 × 1H, 2d, J = 12.2 Hz in each, PhCH2), 4.65, 4.22 (2 × 
1H, 2d, J = 11.3 Hz in each, PhCH2), 4.38 (1H, d, J = 9.5 Hz, H-1′), 3.94 (1H, pt, J = 9.5, 9.2 Hz, H-3′ or 
H-4′), 3.85 (1H, pt, J = 9.4, 9.3 Hz, H-2′ or H-3′ or H-4′), 3.84 (1H, pt, J = 9.5, 9.3 Hz, H-2′ or H-3′ or H-
4′), 3.79 (1H, dd, J = 11.9, 5.2 Hz, H-6′a), 3.64 (1H, dd, J = 11.9, 1.9 Hz, H-6′b), 3.52-3.49 (1H, m, H-5′); 
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13C NMR (100 MHz, CDCl3) δ (ppm): 168.8, 163.3 (C-2, C-4), 160.5 (C-6), 138.3, 138.1, 137.7, 136.9, 
129.0–127.9 (aromatics), 114.8 (CN), 91.0 (C-5), 87.0, 83.2, 82.2, 79.0, 77.5 (C-1′ – C-5′), 76.2, 75.5, 75.0, 
73.8 (4 × PhCH2), 67.8 (C-6′). ESI-MS positive mode (m/z): Calcd for C39H39N4O5+ [M + H]+ 643.3. Found: 
643.5. 
Ethyl 4-amino-2-(2′,3′,4′,6′-tetra-O-benzyl-β-D-glucopyranosyl)-pyrimidine-5-carboxylate (10b) and 
2-(2′,3′,4′,6′-tetra-O-benzyl-β-D-glucopyranosyl)-6-oxo-1,6-dihydropyrimidine-5-carbonitrile (10c). The 
title compounds were prepared from compound 1 (400 mg, 0.66 mmol) and ethyl 2-cyano-3-
ethoxyacrylate 4 (224 mg, 1.33 mmol) according to general procedure 1. Reaction time: 1 h. 
Purification by column chromatography (EtOAc-hexane = 1:3) yielded 10b as the first and 10c as the 
second fraction. 10b: Yield: 167 mg (37%), colourless syrup. Rf = 0.25 (EtOAc-hexane = 1:2); [α]D = +54 
(c 0.20, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ (ppm): 8.81 (1H, s, H-6), 7.84 (1H, br s, NH2), 7.31–6.97 
(20H, m, aromatics), 6.38 (1H, br s, NH2), 4.93, 4.89 (2 × 1H, 2d, J = 11.2 Hz in each, PhCH2), 4.84, 4.57 
(2 × 1H, 2d, J = 10.7 Hz in each, PhCH2), 4.60, 4.27 (2 × 1H, 2d, J = 11.4 Hz in each, PhCH2), 4.60, 4.27 
(2 × 1H, 2d, J = 12.2 Hz in each, PhCH2), 4.36 (2H, q, i = 7.2 Hz, CH2CH3), 4.36 (1H, d, J = 9.6 Hz, H-1′), 
4.03 (1H, pt, J = 9.6, 9.0 Hz, H-2′), 3.84 (1H, pt, J = 9.2, 9.0 Hz, H-3′), 3.76–3.3.71 (3H, m, H-4′, H-6′a, H-
6′b), 3.65 (1H, ddd, J = 9.5, 4.5, 2.2 Hz, H-5′), 1.40 (3H, t, J = 7.2 Hz, CH2CH3); 13C NMR (100 MHz, 
CDCl3) δ (ppm): 168.9, 166.0, 162.8 (C-2, C-4, COOEt), 159.6 (C-6), 138.8, 138.2, 138.2, 138.1, 128.5–
127.5 (aromatics), 104.3 (C-5), 87.1, 82.9, 81.3, 79.8, 77.3 (C-1′ – C-5′), 75.7, 75.2, 74.8, 73.5 (4 × PhCH2), 
69.1 (C-6′), 61.3 (CH2CH3), 14.4 (CH2CH3). ESI-MS positive mode (m/z): Calcd for C41H44N3O7+ [M + 
H]+ 690.3. Found: 690.5. 10c: Yield: 128 mg (30%), colourless syrup. Rf = 0.23 (EtOAc-hexane = 1:2); 
[α]D = ‒12 (c 0.22, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ (ppm): 12.52 (1H, br s, NH), 8.15 (1H, s, H-
4), 7.33-7.09 (20H, m, aromatics), 4.91, 4.88 (2 × 1H, 2d, J = 11.3 Hz in each, PhCH2), 4.86, 4.60 (2 × 1H, 
2d, J = 10.8 Hz in each, PhCH2), 4.71, 4.46 (2 × 1H, 2d, J = 11.5 Hz in each, PhCH2), 4.54, 4.48 (2 × 1H, 
2d, J = 12.0 Hz in each, PhCH2), 4.37 (1H, d, J = 9.5 Hz, H-1′), 3.86-3.70 (6H, m, H-2′ – H-6′a,b); 13C 
NMR (100 MHz, CDCl3) δ (ppm): 162.9, 160.0 (C-2, C-6), 161.1 (C-4), 138.1, 137.9, 137.6, 137.1, 128.7–
127.9 (aromatics), 113.3 (CN), 103.2 (C-5), 85.8, 79.2, 78.9, 78.2, 77.7 (C-1′ – C-5′), 75.6, 75.2, 74.6, 73.4 
(4 × PhCH2), 69.0 (C-6′). ESI-MS positive mode (m/z): Calcd for C39H38N3O6+ [M + H]+ 644.3. Found: 
644.5. 
Ethyl 2-(2′,3′,4′,6′-tetra-O-benzyl-β-D-glucopyranosyl)-6-oxo-1,6-dihydropyrimidine-5-carboxylate 
(10d). Prepared from compound 1 (400 mg, 0.66 mmol) and diethyl 2-(ethoxymethylene)malonate 5 
(265 µL, 1.33 mmol) according to general procedure 1. Reaction time: 1 h. Purified by column 
chromatography (EtOAc-hexane 1:1) to give 367 mg (80%) colourless syrup. Rf = 0.21 (EtOAc-hexane 
= 1:1); [α]D = +9 (c 0.50, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ (ppm): 11.35 (1H, br s, NH), 8.55 (1H, 
s, H-4), 7.32–7.11 (20H, m, aromatics), 4.88, 4.84 (2 × 1H, 2d, J = 11.2 Hz in each, PhCH2), 4.82, 4.55 (2 
× 1H, 2d, J = 10.9 Hz in each, PhCH2), 4.66, 4.45 (2 × 1H, 2d, J = 11.4 Hz in each, PhCH2), 4.55, 4.48 (2 × 
1H, 2d, J = 12.1 Hz in each, PhCH2), 4.37 (2H, q, J = 7.2 Hz, CH2CH3), 4.37 (1H, d, J = 9.5 Hz, H-1′), 3.86–
3.65 (6H, m, H-2′ – H-6′a,b), 1.38 (3H, t, J = 7.2 Hz, CH2CH3); 13C NMR (90 MHz, CDCl3) δ (ppm): 163.2, 
162.6, 160.0 (C-2, C-6, COOEt), 159.2 (C-4), 138.2, 138.0, 137.6, 137.2, 128.5–127.8 (aromatics), 116.7 (C-
5), 86.1, 79.4, 78.9, 78.4, 77.4 (C-1′ – C-5′), 75.5, 75.0, 74.6, 73.4 (4 × PhCH2), 68.8 (C-6′), 61.3 (CH2CH3), 
14.4 (CH2CH3). ESI-MS positive mode (m/z): Calcd for C41H43N2O8+ [M + H]+ 691.3. Found: 691.4. 
4-Amino-2-(2′,3′,4′,6′-tetra-O-benzyl-β-D-glucopyranosyl)-6-phenylpyrimidine-5-carbonitrile (10e). 
Prepared from compound 1 (400 mg, 0.66 mmol) and 2-benzylidenemalononitrile 6 (204 mg, 1.33 
mmol) according to general procedure 1. Reaction time: 1 h. The title compound precipitated from 
the reaction mixture was a pale yellow amorphous solid. Yield: 373 mg (78%). Rf = 0.41 (EtOAc-hexane 
= 2:3); [α]D = ‒12 (c 0.27, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ (ppm): 9.00 (2H, br s, NH2), 7.96–6.97 
(25H, m, aromatics), 4.96–4.69 (6H, m, PhCH2), 4.73, 4.27 (2 × 1H, 2d, J = 11.3 Hz in each, PhCH2), 4.50 
(1H, d, J = 9.6 Hz, H-1′), 4.03 (1H, pt, J = 9.5, 9.2 Hz, H-4′), 3.98 (1H, pt, J = 9.6, 9.1 Hz, H-2′), 3.85 (1H, 
pt, J = 9.2, 9.1 Hz, H-3′), 3.82 (1H, dd, J = 11.8, 3.8 Hz, H-6′a), 3.66 (1H, dd, J = 11.8, 1.9 Hz, H-6′b), 3.52 
(1H, ddd, J = 9.5, 3.8, 1.9 Hz, H-5′); 13C NMR (100 MHz, CDCl3) δ (ppm): 168.3, 167.9, 165.4 (C-2, C-4, 
C-6), 138.5, 138.2, 137.8, 137.1, 136.0, 131.4, 129.0–127.9 (aromatics), 116.0 (CN), 87.4 (C-5), 87.1, 83.5, 
82.5, 79.0, 77.7 (C-1′ – C-5′), 76.2, 75.6, 75.3, 73.9 (4 × PhCH2), 67.9 (C-6′). ESI-MS positive mode (m/z): 
Calcd for C45H43N4O5+ [M + H]+ 719.3. Found: 791.6. 
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2-(2′,3′,4′,6′-Tetra-O-benzyl-β-D-glucopyranosyl)-4-phenyl-6-oxo-1,6-dihydropyrimidine-5-
carbonitrile (10f). Prepared from compound 1 (400 mg, 0.66 mmol) and ethyl 2-cyano-3-phenylacrylate 
7 (267 mg, 1.33 mmol) according to general procedure 1. Reaction time: 1 h. Purified by column 
chromatography (EtOAc-hexane = 2:3) to give 334 mg (70%) colourless syrup. Rf = 0.51 (EtOAc-hexane 
= 1:1); [α]D = +11 (c 0.25, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ (ppm): 8.07–7.02 (25H, m, aromaics), 
4.98, 4.93 (2 × 1H, 2d, J = 11.2 Hz in each, PhCH2), 4.93, 4.72 (2 × 1H, 2d, J = 10.7 Hz in each, PhCH2), 
4.77, 4.47 (2 × 1H, 2d, J = 11.3 Hz in each, PhCH2), 4.61, 4.53 (2 × 1H, 2d, J = 12.3 Hz in each, PhCH2), 
4.52 (1H, d, J = 9.5 Hz, H-1′), 3.97-3.84 (6H, m, H-2′ – H-6′a,b); 13C NMR (100 MHz, CDCl3) δ (ppm): 
168.7, 162.8, 160.6 (C-2, C-4, C-6), 138.2, 138.1, 137.8, 137.1, 134.6, 132.3, 129.3-127.6 (aromatics), 114.8 
(CN), 97.7 (C-5), 86.1, 79.7, 79.2, 78.7, 78.1 (C-1′ – C-5′), 75.6, 75.4, 74.7, 73.3 (4 × PhCH2), 69.4 (C-6′). 
ESI-MS positive mode (m/z): Calcd for C45H42N3O6+ [M + H]+ 720.3. Found: 720.6. 
Methyl 2-(2′,3′,4′,6′-tetra-O-benzyl-β-D-glucopyranosyl)-4-phenyl-6-oxo-1,6-dihydropyrimidine-5-
carboxylate (10g). Prepared from compound 12g (300 mg, 0.40 mmol) and DDQ (90 mg, 0.40 mmol) 
according to general procedure 3. Purified by column chromatography (EtOAc-hexane = 2:3) to give 
177 mg (59%) pale yellow syrup. Rf = 0.48 (EtOAc-hexane = 1:1); [α]D = +10 (c 0.40, CH2Cl2); 1H NMR 
(360 MHz, CDCl3) δ (ppm): 12.40 (1H, br s, NH), 7.65–7.01 (25H, m, aromatics), 4.93, 4.90 (2 × 1H, 2d, 
J = 11.5 Hz, PhCH2), 4.88, 4.64 (2 × 1H, 2d, J = 10.8 Hz, PhCH2), 4.73, 4.47 (2 × 1H, 2d, J = 11.0 Hz, 
PhCH2), 4.58, 4.54 (2 × 1H, 2d, J = 12.1 Hz, PhCH2), 4.42 (1H, d, J = 9.4 Hz, H-1′), 3.94 (1H, pt, J = 9.2, 
9.0 Hz, H-2′or H-3′ or H-4′), 3.86–3.72 (5H, m, H-2′ and/or H-3′ and/or H-4′, H-5′ – H-6′), 3.64 (3H, s, 
OCH3); 13C NMR (90 MHz, CDCl3) δ (ppm): 166.0, 161.3 (2), 157.9 (C-2, C-4, C-6, COOMe), 138.3, 138.0, 
137.9, 137.2, 136.8, 130.5, 128.5-127.8 (aromatics), 118.4 (C-5), 86.3, 79.2, 79.2, 78.8, 77.8 (C-1′ – C-5′), 
75.7, 75.3, 74.7, 73.4 (4 × PhCH2), 69.0 (C-6′), 52.6 (OCH3). ESI-MS positive mode (m/z): Calcd for 
C46H45N2O8+ [M + H]+ 753.3. Found: 753.6. 
Ethyl 2-(2′,3′,4′,6′-tetra-O-benzyl-β-D-glucopyranosyl)-4-phenyl-6-oxo-1,6-dihydropyrimidine-5-
carboxylate (10h). Prepared from compound 12h (300 mg, 0.40 mmol) and DDQ (90 mg, 0.40 mmol) 
according to general procedure 3. Purified by column chromatography (EtOAc-hexane = 2:3) to give 
159 mg (53%) pale yellow syrup. Rf = 0.50 (EtOAc-hexane = 1 : 1); [α]D = +62 (c 0.23, CH2Cl2); 1H NMR 
(360 MHz, CDCl3) δ (ppm): 12.67 (1H, br s, NH), 7.66–7.02 (25H, m, aromatics), 4.94, 4.91 (2 × 1H, 2d, 
J = 11.2 Hz in each, PhCH2), 4.89, 4.64 (2 × 1H, 2d, J = 10.8 Hz in each, PhCH2), 4.74, 4.49 (2 × 1H, 2d, J 
= 11.2 Hz in each, PhCH2), 4.58, 4.52 (2 × 1H, 2d, J = 12.2 Hz in each, PhCH2), 4.43 (1H, d, J = 9.5 Hz, H-
1′), 4.14 (2H, q, J = 7.1 Hz, CH2CH3), 3.97 (1H, pt, J = 9.2, 9.0 Hz, H-2′ or H-3′ or H-4′), 3.87–3.70 (5H, 
m, H-2′ and/or H-3′ and/or H-4′, H-5′ – H-6′a,b), 1.00 (3H, t, J = 7.1 Hz, CH2CH3); 13C NMR (90 MHz, 
CDCl3) δ (ppm): 165.3, 161.4, 161.3, 157.9 (C-2, C-4, C-6, COOEt), 138.4, 138.1, 137.8, 137.2, 136.9, 130.3, 
128.5-127.7 (aromatics), 118.7 (C-5), 86.4, 79.2 (2), 78.9, 77.8 (C-1′ – C-5′), 75.7, 75.2, 74.7, 73.4 (4 × 
PhCH2), 69.0 (C-6′), 61.6 (CH2CH3), 13.8 (CH2CH3). ESI-MS positive mode (m/z): Calcd for C47H47N2O8+ 
[M + H]+ 767.3. Found: 767.6. 
4-Amino-2-(β-D-glucopyranosyl)-pyrimidine-5-carbonitrile (11a). Prepared from compound 2 (100 
mg, 0.41 mmol) and 2-(ethoxymethylene)malononitrile 3 (101 mg, 0.82 mmol) according to general 
procedure 1. Reaction time: 30 min. Purified by column chromatography (CHCl3-MeOH = 5:1) to give 
85 mg (73%) pale yellow syrup. Rf = 0.31 (CHCl3-MeOH = 3:1); [α]D = +42 (c 0.16, MeOH); 1H NMR 
(400 MHz, CD3OD) δ (ppm): 8.56 (1H, s, H-6), 4.18 (1H, d, J = 9.5 Hz, H-1′), 3.85 (1H, dd, J = 12.2, 1.9 
Hz, H-6′a), 3.70 (1H, dd, J = 12.2, 4.9 Hz, H-6′b), 3.67 (1H, pt, J = 9.5, 9.0 Hz, H-2′), 3.50 (1H, pt, J = 9.1, 
9.0 Hz, H-3′), 3.44 (1H, pt, J = 9.4, 9.1 Hz, H-4′), 3.39 (1H, ddd, J = 9.4, 4.9, 1.9 Hz, H-5′); 13C NMR (100 
MHz, CD3OD) δ (ppm): 170.2, 164.4 (C-2, C-4), 161.8 (C-6), 115.4 (CN), 90.8 (C-5), 83.5, 82.3, 79.2, 74.4, 
71.1 (C-1′ – C-5′), 62.7 (C-6′). ESI-HRMS positive mode (m/z): calcd for C11H15N4O5+ [M + H]+ 283.1037; 
C11H14N4NaO5+ [M + Na]+ 305.0856. Found: [M + H]+ 283.1034; [M + Na]+ 305.0852. 
Ethyl 4-amino-2-(β-D-glucopyranosyl)-pirimidine-5-carboxylate (11b) and 2-(β-D-glucopyranosyl)-6-
oxo-1,6-dihydropyrimidine-5-carbonitrile (11c). Method A: The Pd-catalyst (35 mg, 20% Pd(OH)2/C) was 
suspended in an anhydrous EtOAc-EtOH solvent mixture (10 mL in 1:5 ratio) under Ar and the 
suspension was saturatated with H2 (3×). To this heterogenous mixture, a solution of compound 10b 
(70 mg, 0.10 mmol) in EtOAc (1 mL) and one drop of ccHCl were added. The reaction mixture was 
stirred under H2 at rt for two days, and the transformation was monitored by TLC (EtOAc-hexane 
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1:1 and CHCl3-MeOH 7:3). After complete conversion of the starting material, the mixture was 
neutralized with NaHCO3. The catalyst and insoluble inorganic salts were filtered off through a pad 
of Celite and washed three times with MeOH (3 × 3 mL). The resulting combined solution was 
concentrated under diminished pressure and the residue was purified by column chromatography 
(CHCl3-MeOH = 5:1). Yield of compound 11b: 17 mg (51%) colourless syrup. Rf = 0.55 (CHCl3-MeOH 
= 7:3); [α]D = ‒62 (c 0.15, MeOH); 1H NMR (400 MHz, D2O) δ (ppm): 8.82 (1H, s, H-6), 4.37 (2H, q, J = 
7.1 Hz, CH2CH3), 4.28 (1H, d, J = 9.4 Hz, H-1′), 3.93 (1H, dd, J = 12.2, 1.9 Hz, H-6′a), 3.81 (1H, dd, J = 
12.2, 4.5 Hz, H-6′b), 3.73 (1H, pt, J = 9.4, 9.0 Hz, H-2′), 3.69–3.54 (3H, m, H-3′, H-4′, H-5′), 1.38 (3H, t, J 
= 7.1 Hz, CH2CH3); 13C NMR (90 MHz, CD3OD) δ (ppm): 170.4, 166.9, 164.0, 159.7 (C-2, C-4, C-6, 
COOEt), 105.2 (C-5), 83.0, 82.3, 79.3, 74.5, 71.2 (C-1′ – C-5′), 62.9 (C-6′), 62.4 (CH2CH3), 14.5 (CH2CH3). 
ESI-HRMS positive mode (m/z): calcd for C13H20N3O7+ [M + H]+ 330.1296; C13H19N3NaO7+ [M + Na]+ 
352.1115. Found: [M + H]+ 330.1294; [M + Na]+ 352.1114. Method B: The title compounds 11b and 11c 
were prepared from compound 2 (200 mg, 0.82 mmol) and ethyl 2-cyano-3-ethoxyacrylate 4 (279 mg, 
1.65 mmol) according to general procedure 1. Reaction time: 1 h. Purification by column 
chromatography (CHCl3-MeOH = 5:1 → 3:1) yielded 11b (55 mg, 20 %) as the first and 11c 105 mg 
(45%) as the second fraction. Compound 11c: colourless syrup. Rf = 0.39 (CHCl3-MeOH 1:1); [α]D = ‒
66 (c 0.16, MeOH); 1H NMR (400 MHz, CD3OD) δ (ppm): 8.33 (1H, s, H-4), 4.11 (1H, d, J = 9.4 Hz, H-
1′), 3.88 (1H, dd, J = 12.0, 1.8 Hz, H-6′a), 3.71 (1H, dd, J = 12.0, 4.8 Hz, H-6′b), 3.58 (1H, pt, J = 9.3, 9.2 
Hz, H-2′ or H-3′ or H-4′), 3.53–3.41 (3H, m, H-2′ and/or H-3′ and/or H-4′, H-5′); 13C NMR (100 MHz, 
CD3OD) δ (ppm): 173.1, 171.1 (C-2, C-6), 161.4 (C-4), 118.1 (CN), 97.6 (C-5), 81.8, 81.4, 79.1, 74.6, 71.0 
(C-1′ – C-5′), 62.5 (C-6′). ESI-HRMS positive mode (m/z): Calcd. for C11H13NaN3O6+ [M + Na]+ 306.0697. 
Found: 306.0696. 
Ethyl 2-(β-D-glucopyranosyl)-6-oxo-1,6-dihydropyrimidine-5-carboxylate (11d). Method A: The Pd-
catalyst (150 mg, 20% Pd(OH)2/C) was suspended in an anhydrous EtOAc-EtOH solvent mixture (30 
mL in 1:5 ratio) under Ar. This degased suspension was saturatated with H2 (3×). To this 
heterogenous mixture, a solution of compound 10d (335 mg, 0.48 mmol) in EtOAc (3 mL) and three 
drops of ccHCl were added. The reaction mixture was stirred under H2 at rt for two days, and the 
transformation was monitored by TLC (EtOAc-hexane 1:1 and CHCl3-MeOH 7:3). After the complete 
conversion of the starting material, the mixture was neutralized with NaHCO3. The catalyst and the 
insoluble inorganic salts were filtered off through a pad of Celite and washed three times with MeOH 
(3 × 10 mL). The resulting solution was concentrated under reduced pressure and the residue was 
purified by column chromatography (CHCl3-MeOH = 3:1). Yield: 107 mg (67%), colourless syrup. 
Method B: Prepared from compound 2 (100 mg, 0.41 mmol) and diethyl 2-
(ethoxymethylene)malonate 5 (165 µL, 0.82 mmol) according to general procedure 1. Reaction time: 
1 h. Purified by column chromatography (CHCl3-MeOH = 3:1) to give 70 mg (51%) colourless syrup. 
Rf = 0.38 (CHCl3-MeOH = 1:1); [α]D = +75 (c 0.15, MeOH); 1H NMR (360 MHz, D2O) δ (ppm): 8.70 (1H, 
s, H-4), 4.39–4.32 (3H, m, H-1′, CH2CH3), 3.94 (1H, dd, J = 12.2, 2.4 Hz, H-6′a), 3.82 (1H, dd, J = 12.2, 
4.0 Hz, H-6′b), 3.72–3.60 (4H, m, H-2′ – H-5′), 1.36 (3H, t, J = 6.9 Hz, CH2CH3); 13C NMR (90 MHz, D2O) 
δ (ppm): 167.2, 166.7, 164.9, 157.3 (C-2, C-4, C-6, COOEt), 114.2 (C-5), 80.4, 79.7, 77.3, 73.0, 69.7 (C-1′ – 
C-5′), 62.8 (C-6′), 61.2 (CH2CH3), 14.0 (CH2CH3). ESI-HRMS positive mode (m/z): calcd for C13H19N2O8+ 
[M + H]+ 331.1136; C13H18N2NaO8+ [M + Na]+ 353.0955. Found: [M + H]+ 331.1140; [M + Na]+ 353.0953. 
4-Amino-2-(β-D-glucopyranosyl)-6-phenyl-pirimidine-5-carbonitrile (11e). Prepared from compound 
2 (50 mg, 0.21 mmol) and 2-benzylidenemalononitrile 6 (64 mg, 0.41 mmol) according to general 
procedure 1. Reaction time: 1 h. Purified by column chromatography (CHCl3-MeOH = 3:1) to give 63 
mg (85%) pale yellow syrup. Rf = 0.49 (CHCl3-MeOH 7:3); [α]D = +34 (c 0.17, MeOH); 1H NMR (400 
MHz, CD3OD) δ (ppm): 7.89-7.87 (2H, d, J = 7.9 Hz, Ph), 7.57–7.50 (3H, m, Ph ), 4.29 (1H, d, J = 9.6 Hz, 
H-1′), 3.86 (1H, dd, J = 12.1, 2.1 Hz, H-6′a), 3.81 (1H, pt, J = 9.5, 9.3 Hz, H-2′), 3.77 (1H, dd, J = 12.1, 4.7 
Hz, H-6′b), 3.59–3.52 (2H, m, H-3′, H-4′), 3.45–3.42 (1H, m, H-5′); 13C NMR (100 MHz, CD3OD) δ 
(ppm): 170.4, 169.5, 166.2 (C-2, C-4, C-6), 137.5, 132.2, 129.9, 129.8, 129.6 (2) (Ph), 116.4 (CN), 90.8 (C-
5), 87.8, 83.8, 82.2, 79.0, 70.9 (C-1′ – C-5′), 62.4 (C-6′). ESI-HRMS positive mode (m/z): Calcd for 
C17H19N4O5+ [M + H]+ 359.1350; C13H18N2NaO8+ [M + Na]+ 381.1169. Found: [M + H]+ 359.1350; [M + 
Na]+ 381.1169. 
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2-(β-D-Glucopyranosyl)-4-phenyl-6-oxo-1,6-dihydropyrimidine-5-carbonitrile (11f). Prepared from 
compound 2 (50 mg, 0.21 mmol) and ethyl 2-cyano-3-phenylacrylate 7 (83 mg, 0.41 mmol) according 
to general procedure 1. Reaction time: 1 h. Purified by column chromarography (CHCl3-MeOH = 7:3) 
to give 30 mg (41%) colourless syrup. Rf = 0.21 (CHCl3-MeOH 7:3); [α]D = +23 (c 0.16, MeOH); 1H NMR 
(360 MHz, D2O) δ (ppm): 7.81 (2H, d, J = 6.9 Hz, Ph), 7.64–7.58 (3H, m, Ph), 4.31 (1H, d, J = 9.5 Hz, H-
1′), 3.91–3.78 (3H, m, H-2′, H-6′a, H-6′b), 3.69–3.60 (3H, m, H-3′ – H-5′); 13C NMR (90 MHz, D2O) δ 
(ppm): 173.2, 171.1, 167.5 (C-2, C-4, C-6), 136.3, 131.7, 129.3 (2), 129.0 (2) (Ph), 118.7 (CN), 95.1 (C-5), 
81.9, 80.4, 77.5, 73.3, 69.7 (C-1′ – C-5′), 61.1 (C-6′). ESI-HRMS positive mode (m/z): Calcd for 
C17H18N3O6+ [M + H]+ 360.1190; C17H17N3NaO6+ [M + Na]+ 382.1010. Found: [M + H]+ 360.1190; [M + 
Na]+ 382.1009. 
Methyl 2-(β-D-glucopyranosyl)-4-phenyl-6-oxo-1,6-dihydropyrimidine-5-carboxylate (11g). The Pd-
catalyst (50 mg, 20% Pd(OH)2/C) was suspended in anhydrous EtOH (10 mL) under Ar. This degased 
suspension was saturatated with H2 (3×). To this heterogenous mixture, a solution of compound 10g 
(200 mg, 0.27 mmol) in anhydrous EtOAc (2 mL) was added. The reaction mixture was heated at 
reflux temperature under H2 atmosphere until the TLC indicated (EtOAc-hexane 1:1 and CHCl3-
MeOH 4:1) the complete conversion of the starting material (6 h). After the completion of the reaction, 
the catalyst was filtered off through a pad of Celite, and washed with MeOH (3 × 5 mL). The combined 
organic solution was concentrated under reduced pressure and the crude product was purified by 
column chromatography (CHCl3-MeOH = 8:1). Yield: 73 mg (70%), colourless syrup. Rf = 0.43 (CHCl3-
MeOH = 7:1); [α]D = +37 (c 0.18, MeOH); 1H NMR (400 MHz, CD3OD) δ (ppm): 7.63–7.43 (5H, m, Ph), 
4.28 (1H, d, J = 9.5 Hz, H-1′), 3.90 (1H, dd, J = 12.0, 2.0 Hz, H-6′a), 3.79 (1H, dd, J = 12.0, 4.3 Hz, H-6′b), 
3.68 (3H, s, OCH3), 3.65 (1H, pt, J = 9.5, 9.2 Hz, H-2′), 3.55–3.43 (3H, m, H-3′, H-4′, H-5′); 13C NMR (100 
MHz, CD3OD) δ (ppm): 167.7, 162.8, 162.2, 161.2 (C-2, C-4, C-6, COOMe), 137.9, 131.6, 129.6 (2), 129.2 
(2) (Ph), 119.4 (C-5), 82.1, 80.0, 78.8, 74.0, 70.5 (C-1′ – C-5′), 62.2 (C-6′), 53.0 (OCH3). ESI-HRMS positive 
mode (m/z): Calcd for C18H21N2O8+ [M + H]+ 393.1292; C18H20N2NaO8+ [M + Na]+ 415.1112. Found: [M 
+ H]+ 393.1292; [M + Na]+ 415.1111. 
Ethyl 2-(β-D-glucopyranosyl)-4-phenyl-6-oxo-1,6-dihydropyrimidine-5-carboxylate (11h). The Pd-
catalyst (50 mg, 20% Pd(OH)2/C) was suspended in anhydrous EtOH (10 mL) under Ar, and the 
suspension was saturatated with H2 (3×). To this heterogenous mixture, a solution of compound 11h 
(200 mg, 0.26 mmol) in anhydrous EtOAc (2 mL) was added. The reaction mixture was heated at 
reflux temperature under H2 atmosphere until the TLC indicated (EtOAc-hexane 1:1 and CHCl3-
MeOH 4:1) the complete conversion of the starting material (6 h). After completion of the reaction, 
the catalyst was filtered off through a pad of Celite, and washed with MeOH (3 × 5 mL). The combined 
organic solution was concentrated under reduced pressure and the crude product was purified by 
column chromatography (CHCl3-MeOH = 8:1). Yield: 61 mg (58%), colourless syrup. Rf = 0.43 (CHCl3-
MeOH = 7:1); [α]D = +62 (c 0.11, MeOH); 1H NMR (400 MHz, CD3OD) δ (ppm): 7.63–7.43 (5H, m, Ph), 
4.28 (1H, d, J = 9.5 Hz, H-1′), 4.16 (2H, q, J = 7.1 Hz, CH2CH3), 3.90 (1H, dd, J = 11.9, 2.0 Hz, H-6′a), 3.79 
(1H, dd, J = 11.9, 4.3 Hz, H-6′b), 3.64 (1H, pt, J = 9.5, 9.1 Hz, H-2′), 3.54-3.46 (3H, m, H-3′, H-4′, H-5′), 
1.08 (3H, t, J = 7.1 Hz, CH2CH3); 13C NMR (90 MHz, CD3OD) δ (ppm): 167.2, 162.9, 162.2, 161.2 (C-2, 
C-4, C-6, COOEt), 138.1, 131.5, 129.5 (2), 129.3 (2) (Ph), 119.7 (C-5), 82.1, 80.1, 78.8, 74.0, 70.5 (C-1′ – C-
5′), 62.8 (C-6′), 62.2 (CH2CH3), 14.0 (CH2CH3). ESI-HRMS positive mode (m/z): calcd for C19H23N2O8+ 
[M + H]+ 407.1449; C19H22N2NaO8+ [M + Na]+ 429.1268. Found: [M + H]+ 407.1445; [M + Na]+ 429.1262. 
Methyl 2-(2′,3′,4′,6′-tetra-O-benzyl-β-D-glucopyranosyl)-4-phenyl-6-oxo-1,4,5,6-tetrahydropyrimi-
dine-5-carboxylate (12g). Prepared from compound 1 (400 mg, 0.66 mmol) and dimethyl 
benzylidenemalonate 8 (292 mg, 1.33 mmol) according to general procedure 2. Purified by column 
chromatography (EtOAc-hexane = 2:3) to give 451 mg (90%) colourless syrup. Rf = 0.46 (EtOAc-hexane 
= 2:3). 1H NMR (400 MHz, CDCl3) δ (ppm): 8.74, 8.67 (br s, 2 × NH), 7.33–7.10 (m, aromatics), 5.00 (d, 
J = 13.5 Hz, H-4 or H-5), 4.94 (d, J = 11.6 Hz, H-4 or H-5), 4.87–4.48 (m, PhCH2), 4.10, 4.05 (2d, J = 9.1 
Hz in each, 2 × H-1′), 3.79–3.55 (m, 2 × [H-2′ – H-6′a,b]), 3.61, 3.55 (2s, 2 × OMe), 3.49 (d, J = 11.5 Hz, 
H-4 or H-5), 3.22 (d, J = 13.8 Hz, H-4 or H-5); 13C NMR (100 MHz, CDCl3) δ (ppm): 168.3, 168.1, 166.2 
(2) (2 × [C-6, COOMe]), 150.7, 150.5 (2 × C-2), 139.9 (2), 138.4, 138.2, 138.0, 137.9, 137.9, 137.8, 137.7 (2), 
128.8-127.2 (aromatics), 86.3 (2), 79.2, 79.1, 79.1, 78.9, 78.7 (2), 77.4 (2) (2 × [C-1′ – C-5′]), 75.7 (2), 75.2 
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(2), 74.8 (2), 73.6, 73.6 (8 × PhCH2), 68.8, 68.6 (2 × C-6′), 61.5, 61.4, 53.8, 53.7, 52.7, 52.7 (2 × [C-4, C-5, 
OCH3]). ESI-HRMS positive mode (m/z): Calcd for C46H47N2O8+ [M + H]+ = 755.3. Found: 755.5.  
Ethyl 2-(2′,3′,4′,6′-tetra-O-benzyl-β-D-glucopyranosyl)-4-phenyl-6-oxo-1,4,5,6-tetrahydropyrimidine-
5-carboxylate (12h). Prepared from compound 2 (400 mg, 0.66 mmol) and diethyl benzylidinemalonate 
9 (329 mg, 1.33 mmol) according to general procedure 2. Purified by column chromatography 
(EtOAc-hexane = 2:3) to give 413 mg (81%) colourless syrup. Rf = 0.46 (EtOAc-hexane = 2:3). 1H NMR 
(400 MHz, CDCl3) δ (ppm): 8.68, 8.60 (br s, 2 × NH), 7.36–7.11 (m, aromatics), 4.99 (d, J = 13.3 Hz, H-4 
or H-5), 4.92 (d, J = 11.8 Hz, H-4 or H-5), 4.90-4.49 (m, PhCH2), 4.08, 4.07 (2q, J = 7.1 Hz in each, 2 × 
CH2CH3), 4.05, 4.01 (2d, J = 9.1 Hz in each, 2 × H-1′), 3.79–3.53 (m, 2 × [H-2′ – H-6′]), 3.47 (d, J = 11.8 
Hz, H-4 or H-5), 3.20 (d, J = 13.4 Hz, H-4 or H-5), 1.08, 1.06 (2t, J = 7.1 Hz in each, 2 × CH2CH3); 13C 
NMR (100 MHz, CDCl3) δ (ppm): 167.8, 167.6, 166.3, 166.2 (2 × C-6, 2 × COOEt), 150.7, 150.5 (2 × C-2), 
139.9, 139.9, 138.4, 138.2, 138.0, 137.9, 137.9, 137.8, 137.7, 137.7, 128.7–127.3 (aromatics), 86.3 (2), 79.2, 
79.1, 79.1, 78.9, 78.7, 78.7, 77.5, 77.4 (2 × [C-1′ – C-5′]), 75.7 (2), 75.2 (2), 74.8 (2), 73.6, 73.6, (8 × PhCH2), 
68.8, 68.6 (2 × C-6′), 61.8, 61.7 (2 × CH2CH3), 61.6, 61.5, 53.8 (2) (2 × C-4, 2 × C-5), 14.0, 14.0 (2 × CH2CH3). 
ESI-MS positive mode (m/z): Calcd for C47H49N2O8+ [M + H]+ 769.4. Found: 769.6. 
2-Bromo-1,3-bis(dimethylamino)trimethinium perchlorate (15). 1,3-Bis(dimethylamino)trimethinium 
perchlorate 13 (5 g, 22.06 mmol) and NBS (3.93 g, 22.06 mmol) were stirred in dry CH2Cl2 at rt for 5 
h. The solvent was then removed under diminished pressure and the residue was triturated with cold 
EtOH (15 mL) and the precipitate was filtered off. The obtained pale yellow solid (yield: 6.67 g, 99%) 
was used in the next step without further purification. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 7.95 
(2H, s), 3.43 (6H, s), 3.23 (6H, s); 13C NMR (100 MHz, DMSO-d6) δ (ppm): 161.9, 75.9, 49.4, 39.8. 
2-(2′,3′,4′,6′-Tetra-O-benzyl-β-D-glucopyranosyl)-pyrimidine (17a). Prepared from amidine 1 (200 
mg, 0.33 mmol) and 1,3-bis(dimethylamino)trimethinium perchlorate 13 (82 mg, 0.36 mmol) 
according to general procedure 4. Reaction time: 16 h. Purified by column chromatography (EtOAc-
hexane = 1:2) to give 120 mg (60 %) white solid. Mp: 87–89 °C; Rf = 0.45 (EtOAc-hexane = 1:1); [α]D = 
+66 (c 0.27, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ (ppm): 8.72 (2H, d, J = 4.9 Hz, H-4, H-6), 7.34–6.85 
(21H, m, aromatics, H-5), 4.94, 4.91 (2 × 1H, 2d, J = 11.2 Hz, PhCH2), 4.85, 4.57 (2 × 1H, 2d, J = 10.8 Hz, 
PhCH2), 4.59, 4.16 (2 × 1H, 2d, J = 11.3 Hz, PhCH2), 4.57 (1H, d, J = 9.6 Hz, H-1′), 4.55, 4.50 (2 × 1H, 2d, 
J = 12.2 Hz, PhCH2), 4.15 (1H, pt, J = 9.6, 9.2 Hz, H-2′), 3.90 (1H, pt, J = 9.2, 9.1 Hz, H-3′), 3.77–3.70 (4H, 
m, H-4′ – H-6′a,b); 13C NMR (100 MHz, CDCl3) δ (ppm): 166.5 (C-2), 157.3 (C-4, C-6), 138.8, 138.2, 138.1 
(2), 128.5-127.5 (aromatics), 120.6 (C-5), 87.2, 83.2, 81.4, 79.9, 78.4 (C-1′ – C-5′), 75.7, 75.2, 74.7, 73.5 (4 × 
PhCH2), 69.3 (C-6′). ESI-MS positive mode (m/z): Calcd for C38H39N2O5+ [M + H]+ 603.3; Found: [M + 
H]+ 603.5. 
2-(2′,3′,4′,6′-Tetra-O-benzyl-β-D-glucopyranosyl)-5-chloropyrimidine (17b). Prepared from amidine 
1 (200 mg, 0.33 mmol) and 2-chloro-1,3-bis(dimethylamino)trimethinium hexafluorophosphate 14 
(111 mg, 0.36 mmol) according to general procedure 4. Reaction time: 6 h. Purified by column 
chromatography (EtOAc-hexane = 1:3) to give 205 mg (97%) white solid. Mp: 68–70 °C; Rf = 0.40 
(EtOAc-hexane = 1 : 3); [α]D = +4 (c 0.25, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ (ppm): 8.54 (2H, s, H-
4, H-6), 7.36–6.86 (20H, m, aromatics), 4.94 (2H, s, PhCH2), 4.85, 4.56 (2 × 1H, 2d, J = 10.7 Hz, PhCH2), 
4.64, 4.26 (2 × 1H, 2d, J = 11.6 Hz, PhCH2), 4.52 (1H, d, J = 9.7 Hz, H-1′), 4.54, 4.49 (2 × 1H, 2d, J = 12.4 
Hz, PhCH2), 4.06 (1H, pt, J = 9.7, 9.3 Hz, H-2′), 3.89 (1H, pt, J = 9.3, 9.2 Hz, H-3′), 3.75–3.67 (4H, m, H-
4′ – H-6′a,b); 13C NMR (100 MHz, CDCl3) δ (ppm): 164.1 (C-2), 155.6 (C-4, C-6), 138.7, 138.2, 138.1, 
138.0, 128.6–127.5 (aromatics), 130.8 (C-5), 87.3, 82.3, 80.9, 79.9, 78.4 (C-1′ – C-5′), 75.8, 75.2, 74.7, 73.6 
(4 × PhCH2), 69.2 (C-6′). ESI-MS positive mode (m/z): Calcd for C38H38ClN2O5+ [M + H]+ 637.2464; 
C38H37ClN2NaO5+ [M + Na]+ 659.2283. Found: [M + H]+ 637.2464; [M + Na]+ 659.2284. 
2-(2′,3′,4′,6′-Tetra-O-benzyl-β-D-glucopyranosyl)-5-bromopyrimidine (17c). Prepared from amidine 
1 (200 mg, 0.33 mmol) and 2-bromo-1,3-bis(dimethylamino)trimethinium perchlorate 15 (111 mg, 0.36 
mmol) according to general procedure 4. Reaction time: 6 h. Purified by column chromatography 
(EtOAc-hexane = 1:3) to give 203 mg (90%) white amorphous solid. Rf = 0.48 (EtOAc-hexane = 1:2); 
[α]D = +69 (c 0.17, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ (ppm): 8.62 (2H, s, H-4, H-6), 7.36–6.86 (20H, 
m, aromatics), 4.94 (2H, s, PhCH2), 4.85, 4.57 (2 × 1H, 2d, J = 10.8 Hz, PhCH2), 4.64, 4.28 (2 × 1H, 2d, J = 
11.6 Hz, PhCH2), 4.54, 4.48 (2 × 1H, 2d, J = 12.2 Hz, PhCH2), 4.50 (1H, d, J = 9.6 Hz, H-1′), 4.06 (1H, pt, 
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J = 9.6, 9.2 Hz, H-2′), 3.89 (1H, pt, J = 9.2, 9.1 Hz, H-3′), 3.75–3.67 (4H, m, H-4′ – H-6′a,b); 13C NMR (100 
MHz, CDCl3) δ (ppm): 164.3 (C-2), 157.7 (C-4, C-6), 138.6, 138.1, 138.0, 137.9, 128.5–127.5 (aromatics), 
119.9 (C-5), 87.3, 82.3, 80.8, 79.9, 78.3 (C-1′ – C-5′), 75.7, 75.2, 74.6, 73.5 (4 × PhCH2), 69.1 (C-6′). ESI-MS 
positive mode (m/z): Calcd for C38H38BrN2O5+ [M + H]+ 681.1959; C38H37BrN2NaO5+ [M + Na]+ 703.1778. 
Found: [M + H]+ 681.1965; [M + Na]+ 703.1782. 
2-(2′,3′,4′,6′-Tetra-O-benzyl-β-D-glucopyranosyl)-pyrimidine-5-carbaldehyde (17d). Prepared from 
amidine 1 (200 mg, 0.33 mmol) and 2-dimethylaminomethylene-1,3-bis(dimethylimonio)propane 
diperchlorate 16 (139 mg, 0.36 mmol) according to general procedure 4. Reaction time: 4 h. Purified 
by column chromatography (EtOAc-hexane = 1:2) to give 180 mg (86%) white solid. Mp: 80–82 °C; Rf 
= 0.62 (EtOAc-hexane = 1:1); [α]D = +80 (c 0.21, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ (ppm): 10.06 
(1H, s, CHO), 9.01 (2H, s, H-4, H-6), 7.36–6.84 (20H, m, aromatics), 4.94 (2H, s, PhCH2), 4.86, 4.58 (2 × 
1H, 2d, J = 10.7 Hz, PhCH2), 4.65, 4.25 (2 × 1H, 2d, J = 11.6 Hz, PhCH2), 4.63 (1H, d, J = 9.5 Hz, H-1′), 
4.54, 4.49 (2 × 1H, 2d, J = 12.2 Hz, PhCH2), 4.12 (1H, pt, J = 9.5, 9.3 Hz, H-2′), 3.92 (1H, pt, J = 9.2, 9.1 
Hz, H-3′), 3.77-3.69 (4H, m, H-4′ – H-6′); 13C NMR (100 MHz, CDCl3) δ (ppm): 188.8 (CHO), 170.3 (C-
2), 158.2 (C-4, C-6), 138.6, 138.1, 138.0, 137.9, 128.6–127.5 (aromatics), 127.7 (C-5), 87.3, 82.7, 81.0, 80.0, 
78.3 (C-1′ – C-5′), 75.8, 75.3, 74.7, 73.6 (4 × PhCH2), 69.2 (C-6′). ESI-MS positive mode (m/z): Calcd for 
C39H39N2O6+ [M + H]+ 631.2803; C39H38N2NaO6+ [M + Na]+ 653.2622. Found: [M + H]+ 631.2806; [M + 
Na]+ 653.2626. 
2-(2′,3′,4′,6′-Tetra-O-benzyl-β-D-glucopyranosyl)-5-phenylpyrimidine (17e). Compound 17c (380 
mg, 0.56 mmol), phenylboronic acid (136 mg, 1.12 mmol, 2 equiv.), Pd(PPh3)2Cl2 (79 mg, 0.11 mmol, 
0.2 equiv.), Cs2CO3 (363 mg, 1.12 mmol, 2 equiv.), and Bu4NF (1.12 mL, 1.12 mmol, 2 equiv., 1M 
solution in dry THF) were heated at 100 °C in dry 1,4-dioxane (10 mL). After 16 h, the solvent was 
removed under diminished pressure and the residue was purified by column chromatography 
(EtOAc-hexane = 1:2). Yield: 340 mg (90%), white amorphous solid. Rf = 0.29 (EtOAc-hexane = 1:2); 
[α]D = +55 (c 0.27, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ (ppm): 8.86 (2H, s, H-4, H-6), 7.56–6.87 (25H, 
m, aromatics), 4.97, 4.94 (2 × 1H, 2d, J = 11.1 Hz, PhCH2), 4.87, 4.59 (2 × 1H, 2d, J = 10.8 Hz, PhCH2), 
4.65, 4.28 (2 × 1H, 2d, J = 11.4 Hz, PhCH2), 4.63 (1H, d, J = 9.6 Hz, H-1′), 4.56, 4.50 (2 × 1H, 2d, J = 12.2 
Hz, PhCH2), 4.20 (1H, pt, J = 9.6, 9.3 Hz, H-2′), 3.93 (1H, pt, J = 9.3, 9.1 Hz, H-3′), 3.80–3.72 (4H, m, H-
4′ – H-6′a,b); 13C NMR (100 MHz, CDCl3) δ (ppm): 165.0 (C-2), 155.1 (C-4, C-6), 138.7, 138.1 (3), 134.2, 
133.2, 129.5–127.1 (aromatics, C-5), 87.3, 82.9, 81.2, 79.8, 78.4 (C-1′ – C-5′), 75.7, 75.2, 74.7, 73.5 (4 × 
PhCH2), 69.2 (C-6′). ESI-MS positive mode (m/z): Calcd for C44H43N2O5+ [M + H]+ 679.3. Found: [M + 
H]+ 679.6. 
Methyl 2-(2′,3′,4′,6′-tetra-O-benzyl-β-D-glucopyranosyl)-pyrimidine-5-carboxylate (17f). To a 
solution of compound 17d (100 mg, 0.16 mmol) in dry CH3CN (2 mL) NIS (107 mg, 0.48 mmol, 3 
equiv.), K2CO3 (67 mg, 0.48 mmol, 3 equiv.) and MeOH (32 µL, 0.79 mmol, 5 equiv.) were added. The 
reaction mixture was stirred at rt until the TLC (EtOAc-hexane = 2:3) showed complete 
transformation of the starting material (5 h). The reaction was then quenched with 10% aq. solution 
of Na2S2O3 (10 mL) and the mixture was extracted with EtOAc (3 × 10 mL). The combined organic 
phase was washed with brine (10 mL), dried over MgSO4, filtered, and the solvent was removed 
under diminished pressure. Column chromatographic purification of the residue (EtOAc-hexane = 
1:2) gave 72 mg (69%) white amorphous solid. Rf = 0.33 (EtOAc-hexane = 1:2); [α]D = +53 (c 0.20, 
CH2Cl2); 1H NMR (400 MHz, CDCl3) δ (ppm): 9.14 (2H, s, H-4, H-6), 7.36–6.84 (20H, m, aromatics), 
4.94 (2H, s, PhCH2), 4.86, 4.58 (2 × 1H, 2d, J = 10.8 Hz, PhCH2), 4.61, 4.21 (2 × 1H, 2d, J = 11.5 Hz, 
PhCH2), 4.61 (1H, d, J = 9.6 Hz, H-1′), 4.55, 4.49 (2 × 1H, 2d, J = 12.2 Hz, PhCH2), 4.11 (1H, pt, J = 9.6, 
9.3 Hz, H-2′), 3.99 (3H, s, OCH3), 3.91 (1H, pt, J = 9.3, 9.1 Hz, H-3′), 3.77–3.69 (4H, m, H-4′ – H-6′a,b); 
13C NMR (100 MHz, CDCl3) δ (ppm): 169.4, 164.1 (COOMe, C-2), 158.2 (C-4, C-6), 138.6, 138.1, 138.0, 
137.8, 128.5–127.5 (aromatics), 123.1 (C-5), 87.2, 82.7, 8, 1.0, 79.9, 78.3 (C-1′ – C-5′), 75.8, 75.2, 74.7, 73.5 
(4 × PhCH2), 69.1 (C-6′), 52.8 (OCH3). ESI-MS positive mode (m/z): Calcd for C40H41N2O7+ [M + H]+ 
661.3. Found: [M + H]+ 661.6. 
2-(β-D-Glucopyranosyl)-pyrimidine (18a). Method A: Prepared from amidine 2 (100 mg, 0.41 mmol) 
and 1,3-bis(dimethylamino)trimethinium perchlorate 13 (103 mg, 0.45 mmol) according to general 
procedure 4. Reaction time: 16 h. Purified by column chromatography (CHCl3-MeOH = 5:1) to give 
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81 mg (81%) colourless syrup. Method B: Compound 17a (200 mg, 0.33 mmol) was dissolved in 
anhydrous CH2Cl2 (10 mL). The stirred reaction mixture was cooled to ‒78 °C and ~1M solution of 
BCl3 in CH2Cl2 (1.7 mL, 1.7 mmol, 5 eqiuv.) was added. The stirring was continued at this temperature 
and the reaction was monitored by TLC (EtOAc-hexane = 1:2 and CHCl3-MeOH = 3:1). After the 
complete disappearance of the starting material (3 h), MeOH (15 mL) was added to the reaction 
mixture and was left to warm to rt. The solvents were removed under diminished pressure and the 
residue was purified by column chromatography (CHCl3-MeOH = 5:1) to give 68 mg (85%) colourless 
syrup. Rf = 0.28 (CH3Cl-MeOH = 7:3); [α]D = +44 (c 0.24, H2O); 1H NMR (360 MHz, CD3OD) δ (ppm): 
8.84 (2H, d, J = 5.0 Hz, H-4, H-6), 7.48 (1H, t, J = 5.0 Hz, H-5), 4.44 (1H, d, J = 9.6 Hz, H-1′), 3.88 (1H, 
dd, J = 12.2, 1.7 Hz, H-6′a), 3.76 (1H, pt, J = 9.5, 9.1 Hz, H-2′), 3.72 (1H, dd, J = 12.2, 4.7 Hz, H-6′b), 3.58 
(1H, pt, J = 9.1, 9.0 Hz, H-3′ or H-4′), 3.52 (1H, pt, J = 9.3, 9.1 Hz, H-3′ or H-4′), 3.49–3.46 (1H, m, H-5′); 
13C NMR (90 MHz, CD3OD) δ (ppm): 167.9 (C-2), 158.7 (2) (C-4, C-6), 122.2 (C-5), 83.6, 82.3, 79.3, 74.8, 
71.2 (C-1′ – C-5′), 62.7 (C-6′). ESI-MS positive mode (m/z): C10H14N2NaO5+ [M + Na]+ 265.0795. Found: 
265.0795. 
5-Chloro-2-(β-D-glucopyranosyl)-pyrimidine (18b). Prepared from amidine 2 (100 mg, 0.41 mmol) 
and 2-chloro-1,3-bis(dimethylamino)trimethinium hexafluorophosphate 14 (139 mg, 0.45 mmol) 
according to general procedure 4. Reaction time: 2 h. Purified by column chromatography (CHCl3-
MeOH = 9:1) to give 100 mg (88%) white solid. Mp: 200–202 °C; Rf = 0.25 (CH3Cl-MeOH = 5:1); [α]D = 
‒11 (c 0.22, H2O); 1H NMR (360 MHz, CD3OD) δ (ppm): 8.87 (2H, s, H-4, H-6), 4.43 (1H, d, J = 9.6 Hz, 
H-1′), 3.87 (1H, dd, J = 12.3, 1.7 Hz, H-6′a), 3.76 (1H, pt, J = 9.5, 9.1 Hz, H-2′), 3.70 (1H, dd, J = 12.3, 4.8 
Hz, H-6′b), 3.54 (1H, pt, J = 9.2, 9.0 Hz, H-3′ or H-4′), 3.50–3.43 (2H, m, H-3′ or H-4′, H-5′); 13C NMR 
(90 MHz, CD3OD) δ (ppm): 165.9 (C-2), 157.1 (2) (C-4, C-6), 132.1 (C-5), 83.6, 82.6, 79.3, 74.7, 71.4 (C-
1′ – C-5′), 62.8 (C-6′). ESI-MS positive mode (m/z): C10H13ClN2NaO5+ [M + Na]+ 299.0405. Found: 
299.0407. 
5-Bromo-2-(β-D-glucopyranosyl)-pyrimidine (18c). Prepared from amidine 2 (100 mg, 0.41 mmol) 
and 2-bromo-1,3-bis(dimethylamino)trimethinium perchlorate 15 (138 mg, 0.45 mmol) according to 
general procedure 4. Reaction time: 2 h. Purified by column chromatography (CHCl3-MeOH = 9:1) to 
give 112 mg (85%) white solid. Mp: 224–226 °C; Rf = 0.25 (CH3Cl-MeOH = 5:1); [α]D = +19 (c 0.22, H2O); 
1H NMR (360 MHz, CD3OD) δ (ppm): 8.96 (2H, s, H-4, H-6), 4.41 (1H, d, J = 9.6 Hz, H-1′), 3.87 (1H, 
dd, J = 12.2, 1.5 Hz, H-6′a), 3.75 (1H, pt, J = 9.6, 9.1 Hz, H-2′), 3.70 (1H, dd, J = 12.2, 4.6 Hz, H-6′b), 3.54 
(1H, pt, J = 9.3, 9.1 Hz, H-3′ or H-4′), 3.50–3.43 (2H, m, H-3′ or H-4′, H-5′); 13C NMR (90 MHz, CD3OD) 
δ (ppm): 166.2 (C-2), 159.4 (2) (C-4, C-6), 120.9 (C-5), 83.7, 82.6, 79.3, 74.7, 71.4 (C-1′ – C-5′), 62.8 (C-6′). 
ESI-MS positive mode (m/z): C10H13BrN2NaO5+ [M + Na]+ 342.9900. Found: 342.9901. 
2-(β-D-Glucopyranosyl)-5-phenylpyrimidine (18e). Compound 17e (200 mg, 0.29 mmol) was 
dissolved in anhydrous CH2Cl2 (10 mL). The stirred reaction mixture was cooled to ‒78 °C and a ~1M 
solution of BCl3 in CH2Cl2 (1.5 mL, 1.5 mmol, 5 equiv.) was added. The stirring was continued at this 
temperature and the reaction was monitored by TLC (EtOAc-hexane = 1:2 and CHCl3-MeOH = 3:1). 
After the complete disappearance of the starting material (2 h), MeOH (10 mL) was added to the 
reaction mixture and was left to warm to rt. The solvents were removed under diminished pressure 
and the residue was purified by column chromatography (CHCl3-MeOH = 9:1) to give 87 mg (93%) 
colourless syrup. Rf = 0.50 (CH3Cl-MeOH = 3:1); [α]D = –31 (c 0.22, H2O); 1H NMR (360 MHz, CD3OD) 
δ (ppm): 9.07 (2H, s, H-4, H-6), 7.72 (2H, d, J = 7.1 Hz, Ph), 7.56–7.46 (3H, m, Ph), 4.49 (1H, d, J = 9.5 
Hz, H-1′), 3.90 (1H, dd, J = 12.1, 1.7 Hz, H-6′a), 3.81 (1H, pt, J = 9.5, 9.1 Hz, H-2′), 3.74 (1H, dd, J = 12.1, 
4.8 Hz, H-6′b), 3.59 (1H, pt, J = 9.1, 9.0 Hz, H-3′ or H-4′), 3.53 (1H, pt, J = 9.2, 9.0 Hz, H-3′ or H-4′), 3.53–
3.51 (1H, m, H-5′); 13C NMR (90 MHz, CD3OD) δ (ppm): 166.5 (C-2), 156.3 (2) (C-4, C-6), 135.1, 134.9 
(Ph, C-5), 130.6 (2), 130.3, 128.1 (2) (Ph), 83.6, 82.5, 79.4, 74.9, 71.3 (C-1′ – C-5′), 62.9 (C-6′). ESI-MS 
positive mode (m/z): C16H18N2NaO5+ [M + Na]+ 341.1108. Found: 341.1108. 
Methyl 2-(β-D-glucopyranosyl)-pyrimidine-5-carboxylate (18f). Compound 17f (200 mg, 0.30 mmol) 
was dissolved in anhydrous CH2Cl2 (10 mL). The stirred reaction mixture was cooled to ‒78 °C and a 
~1M solution of BCl3 in CH2Cl2 (1.51 mL, 1.51 mmol, 5 equiv.) was added. The stirring was continued 
at this temperature and the reaction was monitored by TLC (EtOAc-hexane = 1:2 and CHCl3-MeOH 
= 3:1). After complete disappearance of the starting material (2 h), MeOH (15 mL) was added to the 
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reaction mixture and was left to warm to rt. The solvents were removed under diminished pressure 
and the residue was purified by column chromatography (CHCl3-MeOH = 9:1) to give 74 mg (81%) 
colourless syrup. Rf = 0.31 (CH3Cl-MeOH = 5:1); [α]D = +51 (c 0.22, H2O); 1H NMR (360 MHz, CD3OD) 
δ (ppm): 9.29 (2H, s, H-4, H-6), 4.52 (1H, d, J = 9.6 Hz, H-1′), 3.99 (3H, s, OCH3), 3.88 (1H, dd, J = 12.2, 
1.7 Hz, H-6′a), 3.78 (1H, pt, J = 9.5, 9.1 Hz, H-2′), 3.72 (1H, dd, J = 12.2, 4.6 Hz, H-6′b), 3.62–3.47 (3H, 
m, H-3′, H-4′, H-5′); 13C NMR (90 MHz, CD3OD) δ (ppm): 171.0 (C=O), 165.1 (C-2), 159.3 (2) (C-4, C-
6), 124.8 (C-5), 83.8, 82.5, 79.3, 74.7, 71.2 (C-1′ – C-5′), 62.8 (C-6′), 53.3 (OCH3). ESI-MS positive mode 
(m/z): C12H16N2NaO7+ [M + Na]+ 323.0850. Found: 323.0851. 
3.2. Enzyme Assays 
The inhibition of rmGPb by the test compounds was investigated with a maximal inhibitory 
concentration of 625 µM by applying a general protocol described earlier [17,27]. 
In the glycosidase assays, the inhibition experiments were made under the same conditions, 
except for buffer composition, substrate and enzyme concentration, which were as follows:  
β-Glucosidase from almonds (Sigma-Aldrich Kft., Budapest, Hungary): 2.5 mM PNP-β-Glc 
substrate in citrate-phosphate buffer pH 5.2 using 0.25 mg/mL of enzyme. 
α-Glucosidase from Saccharomyces cerevisiae (Sigma-Aldrich Kft., Budapest, Hungary): 0.5 mM 
PNP-α-Glc in glycerophosphate buffer pH 6.9 using 0.02 mg/mL of enzyme.  
Bovine liver β-galactosidase (Sigma-Aldrich Kft., Budapest, Hungary): 1 mM PNP-β-Gal in 
citrate-phosphate buffer pH 7.3 using 0.12 mg/mL of enzyme. 
A 10 µL aliquot for each of the different inhibitor stock solutions was mixed with 370 µL of the 
buffer and 20 µL of the enzyme stock solution in a plastic UV cuvette. After equilibration at 37 °C for 
5 min, a 100 µL aliquot of the substrate stock solution was added. The resulting solutions were 
thoroughly mixed, and the change in absorbance was followed at 400 nm over 240 s in 2 s intervals 
using the Parallel Kinetics Analysis program of a JASCO V550 (JASCO Tokyo, Japan) 
spectrophotometer. Progress curves were plotted and fitted to a straight line. ΔA/min values, 
proportional to initial rate, were considered to be enzyme activities. In a control experiment, the 
aliquot of the inhibitor solution was replaced by the same amount of buffer. The initial rate data for 
the enzymatic substrate hydrolysis in the presence and absence of inhibitor were transferred into 
percentages of overall inhibition and plotted against the inhibitor concentration in logarithmic scale 
for IC50 determination. 
4. Conclusion 
New representatives of 2-C-glycopyranosyl pyrimidines, such as 2-C-(β-D-glucopyranosyl)-5,6-
disubstituted-pyrimidin-4(3H)-ones, 4-amino-2-C-(β-D-glucopyranosyl)-5,6-disubstituted-pyrimi-
dines, and 2-C-(β-D-glucopyranosyl)-5-substituted-pyrimidines were synthesized by ring-closures of 
O-perbenzylated and O-unprotected C-(β-D-glucopyranosyl)formamidine hydrochlorides with 
methylenemalonic acid derivatives or vinamidinium salts. The inhibitory activities of the resulting 5-
mono- and 4,5,6-trisubstituted pyrimidines were investigated against some glycoenzymes. While 
none of the new compounds proved to be effective against glycogen phosphorylase and α- and β-
glucosidase enzymes, some aryl and/or ester substituted derivatives displayed modest inhibitory 
potency against bovine liver β-galactosidase. 
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